RetatrutideDosing & Reconstitution Calculator

Retatrutide — A Powerful Next-Gen GLP-1 Drug

Retatrutide is the only compound that activates all three of the hormones your body releases to regulate eating, storing, and burning energy.¹

• Appetite control — GLP-1 (0.4× native). GLP-1 is the hormone your gut releases after a meal to tell your brain "you're full." Retatrutide hits this receptor at 40% of your body's own GLP-1 signal. Semaglutide hits it at 1× native — body-equivalent intensity, which is why nausea and food aversion run highest on sema.
• Fat-cell energy handling — GIP (8.9× native). GIP is the hormone that tells your fat cells how to accept and process incoming energy. Retatrutide hits this receptor at 8.9 times your body's own GIP — nearly 9× higher than tirzepatide.
• Liver fat oxidation — glucagon (0.3× native). Glucagon is what your body releases to tell the liver to burn stored fuel. Retatrutide adds this signal at 30% of your body's own glucagon. Neither sema nor tirz carries it at all. The consequences: direct liver-fat reduction and a 6–10% lift in baseline metabolic rate / energy expenditure.¹

That glucagon arm is what changes the dose math. A higher dose doesn't just suppress appetite more — it makes the body burn harder. The combined effects — and side-effects — are highly dose-dependent, and warrant careful consideration.

Retatrutide's first Phase 3 trial (TRIUMPH-4)¹⁰ produced up to an average 71.2 lb weight loss — 26.4% mean at 9mg and 28.7% at 12mg over 68 weeks² — but the trial enrolled adults with obesity (BMI ≥30), not the average reader. In the earlier Phase 2 trial, the 4mg weekly produced ~17% weight loss over 48 weeks¹ — this time in adults with obesity or overweight plus weight-related comorbidities, but not diabetes.

Both benchmarks come from populations with real metabolic burden going in. Neither the trial ceiling of 12mg nor the 4mg floor is the target — most users focused on weight-loss settle somewhere between 4 and 8mg. If the goal is resetting from a recent period of moderate weight gain, improved blood markers for insulin, HbA1c, and cholesterol, and 'food-noise' suppression — or taking proactive preventative measures for at risk phenotypes (e.g. South Asians, family history of diabetes), micro-dosing (0.5mg-2.0mg) Reta can be a compelling option.

The dose question below has three variables: total weekly dose, injection frequency, and personal phenotype. The ladder is shared. The landing point is not. Retatrutide remains investigational — FDA approval anticipated 2027¹ — so the dose ranges come from trial protocols, user reports, and mechanistic understanding, not an FDA label. Consult with your doctor before starting: the glucagon arm makes this drug more powerful than its predecessors, and the dose-dependent cardiac signal earns that consultation.

Retatrutide Dosing Math — Unique Among GLP-1s

All values normalized against the body's own hormone at each receptor (Jastreboff 2023 NEJM).¹

Reta's GLP-1 signal sits between sema and tirz. Its GIP signal is dramatically stronger than either — 8.9× the body's own, versus tirz's 1.0×. The third axis, glucagon at 0.3× native, is the one that reshapes the dose decision. Glucagon pushes resting energy expenditure (i.e. metabolic rate) up and tells the liver to burn stored fat directly,¹ which means Reta's effect compounds with dose in a way a pure GLP-1 drug doesn't.

A higher dose doesn't just suppress appetite harder — it forces more expenditure. That's why the cardiac signal — HR increase — scales with dose, why the fatigue pattern looks different from semaglutide's, and why the effective maintenance dose for most users sits well below the trial maximum.⁸

The retatrutide deep dive covers the full mechanism, trial cohorts, and body-composition data.

Finding the optimal Reta dose for your goals and needs

Three inputs shape the dose decision: what you're trying to do with the drug, what your baseline tolerates, and how your body responds in the first few weeks.

Before you start, check these

A baseline panel before your first injection makes every subsequent dose decision defensible. Without it, a rising resting heart rate at week 8 can't be distinguished from a drug effect — and the dose conversation becomes guesswork.

• Resting heart rate and rhythm — recorded for a full week at baseline. Reta raises resting HR by 2–3 bpm at low doses and 6–7 bpm at 12mg.³ You need the baseline to know which is which.
• Fasting glucose, HbA1c, fasting insulin — the metabolic starting point. These are how you'll tell whether the dose is doing what you actually want.
• Lipid panel — baseline for Reta's triglyceride and cholesterol effects. Phase 2 obesity data showed ~20% LDL reduction and triglyceride drops in line with weight loss — effects that matter on their own even without pushing toward the weight-loss indication.
• Thyroid panel, including Free T3 — not just TSH. Reta's glucagon-driven energy deficit can downregulate T4-to-T3 conversion during active use, producing fatigue, cold extremities, and brain fog that a standard TSH panel misses.⁹ A pre-existing hyperthyroid state compounds the metabolic strain and is a real reason to consider tirzepatide instead — tirz carries no comparable signal. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is a hard contraindication across the GLP-1 class.
• Additional: Liver enzymes and imaging if MASLD is on the table — hepatic fat reduction is one of Reta's strongest effects, and you want a pre-drug picture to measure against.

Finding your effective Reta dose: 1mg titration steps

The Phase 2 ladder ran in four phases. Do not increase dose in the first four weeks — Reta needs time to build up in your blood plasma. After the start phase, hold each step for at least 2–4 weeks.

The step-duration rule is pharmacokinetic, not stylistic. Reta's half-life is roughly 6 days⁷ — plasma concentration at a new dose step doesn't stabilize for two half-lives — 12 to 18 days. A GI or cardiac response to dose N can arrive after you've already moved to dose N+1, and the next step loads on top of an unresolved reaction.

Pushing through the first four weeks is the single most common way to turn a manageable titration into a miserable one. Starting at 1mg rather than the trial's 2mg buys an additional two weeks of adaptation.³ The cost is nothing besides time, the return is getting retatrutide to work for you.

Even at a low dose, you may experience rapid water-weight loss in the first four weeks — stay hydrated and increase electrolyte intake. Regardless of dose, expect some degree of appetite suppression.

Two stopping rules during the initial start period: if resting HR stays more than 10 bpm above baseline, hold until it settles. If nausea or GI distress from the previous step hasn't resolved, extend step duration — do not increase further.

Typical Reta dose ranges, based on goals and needs

As mentioned, the retatrutide trial top-line numbers (12mg) came from populations with obesity and T2DM. A reader 20 lb over a healthy weight is extrapolating, not matching.

The heart-rate signal scales with every step up — +2–3 bpm at 1–4mg, +6–7 bpm at 12mg, peaking around week 24 before partially settling.³ That cardiac cost is why the effective dose for most people sits in the moderate band. Higher is not automatically better.

What to track during the initial start phase

• Resting HR and rhythm — weekly through titration, biweekly at maintenance. ECG if you have any cardiac history.
• Weight and waist circumference — weekly, same conditions (morning, fasted, post-void). Waist trend is the cleaner signal for visceral-fat response — weight alone conflates fat, water, and lean mass.
• Fasting glucose, HbA1c, fasting insulin — quarterly.
• Lipid panel — quarterly.
• Liver enzymes — quarterly; more often if MASLD is in the picture.
• Free T3 if fatigue appears — standard TSH panels miss the T4-to-T3 suppression pattern Reta can produce.⁹ Don't accept "your TSH is normal" as the end of the conversation.

Reta at 0.5–2mg: the metabolic-health use case

Most content about retatrutide frames it as a powerful weight-loss drug. At sub-therapeutic doses, retatrutide can produce three effects without the side-effect burden that comes with therapeutic doses:

• Food-noise quiets, but hunger doesn't collapse. GLP-1-mediated reduction in reward-driven eating sits lower on the dose curve than the appetite suppression that makes eating difficult. Users at 0.5–2mg often report eating normal meals without thinking about food between them — the distraction goes away, but the capacity to eat does not dramatically diminish.
• Liver fat falls. The MASLD substudy showed ~84% hepatic-fat reduction at 48 weeks at high doses⁵ — substantially more than semaglutide (~30%) or tirzepatide (~47%) on comparable imaging, because the glucagon arm mobilizes hepatic fat directly rather than relying on indirect effects from weight loss. The effect scales with dose but is not binary — glucagon-driven hepatic fat oxidation fires at sub-therapeutic doses too, just more slowly. Visceral-fat reduction likely follows the same pattern, though direct trial data in non-obese populations does not yet exist.
• Glucose and lipid markers improve. Fasting insulin drops, triglycerides fall, and the ApoB / non-HDL profile improves on the same mechanism that drives the weight-loss indication — just without the weight loss as the primary outcome.

This is treating retatrutide as a metabolic-health tool rather than a weight-loss tool. It's the right dose band for someone who is at a relatively healthy weight, has metabolic markers they want to move (early insulin resistance, elevated liver fat on imaging, borderline lipids), or is an at-risk phenotype (e.g. South Asians, family history of diabetes) — but doesn't want to collapse appetite or risk 5–10% lean-mass loss from an aggressive deficit.

Note. No published trial arm tested doses below 1mg; the 0.5mg positioning is mechanism-inferred from the 1mg arm's dose-response curve and the pharmacology of GLP-1 class agonists at sub-therapeutic receptor occupancy. The cardiac signal at this dose band is minimal (+1–2 bpm), but the monitoring logic above still applies. Use for metabolic stability in non-obese populations is extrapolative.⁸

How often should you take retatrutide? The case for splitting a weekly dose

Reta's 6-day half-life⁷ means weekly dosing produces a real peak-trough curve — plasma concentration roughly doubles at the injection peak versus the pre-injection trough. GI side effects and heart-rate response track peak concentration, not the weekly total. Splitting the weekly dose lowers the peak without changing what the body actually receives, which is why splitting often resolves problems that simply cutting the dose cannot.

Splitting a 4mg weekly dose into two 2mg injections cuts the injection-peak concentration roughly in half while delivering the same weekly total. The practical implication: a split schedule extends the dose ceiling you can tolerate before cardiac or GI response forces a hold. At the upper end of the titration range (8–12mg) — where the cardiac signal matters most — splitting isn't just a convenience trade-off. It's a dose-decision lever.

The GLP-1 Dosing Optimizer calculates the exact per-injection dose, peak-trough profile, and plasma curve for any frequency.

Retatrutide Dosage Calculator & Titration Math

Because Retatrutide is a highly potent investigational triple-agonist, accurate dosing during the escalation phase is critical to mitigate gastrointestinal side effects.

The standard clinical research protocol follows a strict 4-week dose escalation:

• Weeks 1–4 (Initiation): 2.0 mg weekly
• Weeks 5–8 (Escalation 1): 4.0 mg weekly
• Weeks 9–12 (Escalation 2): 8.0 mg weekly
• Weeks 13+ (Maintenance): 12.0 mg weekly

Calculating Your Retatrutide Draw Volume

To calculate how much liquid to pull into your syringe, you must establish the concentration of your reconstituted vial.

Formula: (Desired Dose / Total Vial mg) × Diluent Volume (mL) = Draw Volume (mL)

Example calculation for a 2mg Starting Dose:
If you add 2mL of Bacteriostatic Water to a 10mg vial of Retatrutide:

1. (2mg Desired / 10mg Total) = 0.2
2. 0.2 × 2mL BAC Water = 0.4 mL
3. Result: Draw 40 units on a standard U-100 syringe.

To calculate complex transition doses (e.g., moving from 4mg to 6mg) or to manage multi-peptide cocktails, use the PeptideFox AI Wizard for automated, compound-specific logic.

Reconstituting retatrutide with BAC water

Every Reta vial is a fixed amount of peptide sitting at the bottom as a dry cake. Bacteriostatic water is what turns it into a solution you can draw and inject. The volume of water sets the concentration (mg per mL) — more water means lower concentration and a larger, easier-to-read draw. Less water means higher concentration and a smaller injection volume. The total milligrams in the vial don't change — water is a measurement choice, not a potency factor.

New to reconstitution? The PeptideFox reconstitution guide walks through the full process — sterile technique, storage, troubleshooting — with images. Start there if this is your first vial.

How to reconstitute retatrutide

The mechanics are simple but they matter. Rough handling denatures the peptide. Bad technique contaminates the whole vial.

1. Wipe both stoppers (peptide vial and BAC water vial) with an alcohol swab.
2. Calculate the amount of BAC water needed — use an amount that allows for easy dosing.
3. Draw the BAC water into a sterile syringe.
4. Angle the needle so water runs down the inside wall of the peptide vial — not directly onto the cake.
5. Swirl gently. Do not shake. Mechanical agitation denatures peptides. A slow rocking motion dissolves the cake in 30–60 seconds.
6. Refrigerate at 2–8°C between draws. Never freeze reconstituted Reta — freeze-thaw cycles damage the peptide structure.
7. Discard if the solution turns cloudy, discolored, or shows visible particles.
8. Use a fresh syringe and wipe the stopper with alcohol at every draw.

Reconstituted Reta is stable 4–6 weeks at 2–8°C.⁴

Where the vials come from

Reta isn't FDA-approved and isn't dispensed through regular pharmacies — research-grade lyophilized vials are the format most users handle. Quality varies. Ask your supplier for a certificate of analysis before your first order. Among compounders, 503B outsourcing facilities operate under stricter federal oversight than 503A pharmacies; it's worth knowing which you're buying from.

Choosing the right vial size

Match vial size to your weekly dose and the 4–6 week stability window.⁴ Early titration at 1–2mg: 5mg or 10mg vial. Build phase at 4mg: 10mg or 12mg. Effect range at 8mg: 15mg or 20mg. Maintenance at 8–12mg: 20mg, 24mg, or 30mg. A 30mg vial only makes sense at high-dose maintenance where you'll draw it down inside the stability window.

Stopping retatrutide

Without a protocol, weight regain is likely. The STEP-1 extension showed two-thirds regain at 52 weeks after stopping semaglutide, and Reta's curve is probably steeper because the glucagon-driven thermogenic lift also vanishes on discontinuation. The maintenance case — sustaining a lower dose indefinitely rather than discontinuing — tracks the same logic as semaglutide and tirzepatide maintenance: keep enough receptor occupancy to hold the appetite and metabolic effects, with less GI burden than the peak titration dose.

Related Topics

• Retatrutide Deep Dive — mechanism, trial data, cardiac safety, body composition
• GLP-1 Dosing Optimizer — interactive frequency calculator with plasma curves
• Full Reconstitution Calculator — all peptides, cocktails, custom BAC volumes
• Retatrutide Dual-Axis Protocol — advanced stacking for recomposition
• Retatrutide + NAD+ Protocol — cofactor layer during active dosing
• GLP-1 Muscle Preservation — protect lean mass during weight loss
• Tirzepatide Dosing — the approved dual-agonist alternative
• Semaglutide Dosing — the established GLP-1 benchmark

References

¹ Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023: 10.1056/NEJMoa2301972 — dose-response, titration protocol (1–12mg weekly), and weight-loss outcomes.

² Eli Lilly press release, December 11, 2025 — "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis in first successful Phase 3 trial." investor.lilly.com. First Phase 3 efficacy readout for the TRIUMPH program (TRIUMPH-4, NCT05931367, 68 weeks, adults with obesity and knee osteoarthritis). The 28.7% / 26.4% mean weight-loss figures at 12mg / 9mg are consistent with the Lilly-announced 71.2 lb absolute figure at typical cohort starting weight.

³ Rosenstock J, et al. Retatrutide Phase 2 T2D trial, ADA 2023: meeting summary — heart-rate dose-response data (+2–3 bpm low dose, +6–7 bpm at 12mg; benign arrhythmias 4–14% vs 2–3% placebo); GI discontinuation risk by dose band.

⁴ Standard peptide reconstitution and storage guidance — lyophilized retatrutide refrigerated at 2–8°C; reconstituted solution stable 4–6 weeks at 2–8°C; never freeze. Covered in the PeptideFox reconstitution guide.

⁵ Retatrutide MASLD substudy (Nature Medicine 2024): s41591-024-03018-2 — 84–86% liver fat reduction at 48 weeks.

⁶ Retatrutide T2D body composition / DXA substudy (Lancet Diabetes Endocrinol 2025): PMID: 40609566 — 63:37 fat-to-lean ratio in diabetic patients.

⁷ Coskun T, et al. Retatrutide discovery and receptor pharmacology. Cell Metabolism 2022: 10.1016/j.cmet.2022.07.002 — ~6-day half-life, compound discovery. Note: Coskun's receptor-potency table uses tirz-relative normalization, not native-hormone normalization. The native-relative values (GLP-1 0.4×, GIP 8.9×, GCGR 0.3×) come from Jastreboff 2023 NEJM.¹

⁸ Effective dose below trial maximum — extrapolated from Jastreboff 2023 dose-response (4mg arm produced ~17% weight loss vs ~24% at 12mg) and cardiac dose-sensitivity (HR increase scales linearly with dose). Sub-1mg dosing is below any published trial arm; positioning is mechanism-inferred from GLP-1 class behavior at sub-therapeutic receptor occupancy.

⁹ Glucagon-driven T3 suppression during active GLP-1/GIP/glucagon agonism — T4-to-T3 conversion downregulates in response to combined caloric deficit and forced hepatic expenditure; Free T3 drops while TSH remains in range. Covered with monitoring guidance in the GLP-1 fatigue guide.

¹⁰ Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. Published online October 15, 2025: 10.1111/dom.70209 — trial design paper for the four-trial TRIUMPH Phase 3 program (~5,800 participants across obesity, OSA, knee OA, and obesity + CVD). TRIUMPH-4 is NCT05931367.